IP Verse

Synthon B.v. opposition analysis

COMPANY ANALYSIS

Latest oppositions filed by Synthon B.v.

Patent Number:
EP3383385
Title:
Melflufen Dosage Regimens For Cancer
Applicant:
ONCOPEPTIDES AB
Opposition Date:
Apr 28, 2021
Patent Number:
EP3143995
Title:
A Rapamycin Derivative For Treating Lung Cancer
Applicant:
NOVARTIS AG
Opposition Date:
Aug 27, 2019
Patent Number:
EP3199172
Title:
Dosing Regimen For Multiple Sclerosis
Applicant:
YEDA RESEARCH AND DEVELOPMENT CO., LTD.
Opposition Date:
Apr 11, 2019
Patent Number:
EP2630962
Title:
Low Frequency Glatiramer Acetate Therapy
Applicant:
YEDA RESEARCH & DEVELOPMENT COMPANY, LTD.
Opposition Date:
Mar 26, 2019
Patent Number:
EP2949335
Title:
Low Frequency Glatiramer Acetate Therapy
Applicant:
YEDA RESEARCH & DEVELOPMENT COMPANY, LTD.
Opposition Date:
Oct 4, 2017
Patent Number:
EP2269603
Title:
Treatment Of Solid Tumours With Rapamycin Derivatives
Applicant:
NOVARTIS AG
Opposition Date:
Feb 22, 2016

Latest patents of Synthon B.v. opposed by its competitors

Patent:
EP3697392
Grant Date:
Nov 15, 2023
Title:
Tablets Comprising Tamsulosin And Solifenacin
Oppositions:
3
Patent:
EP3606511
Grant Date:
Apr 20, 2022
Title:
Pharmaceutical Composition Comprising Lenvatinib Mesylate
Oppositions:
1
Patent:
EP3206666
Grant Date:
Dec 11, 2019
Title:
Liquid Pharmaceutical Composition Comprising Pemetrexed
Oppositions:
1
Patent:
EP2774606
Grant Date:
Jan 30, 2019
Title:
Pharmaceutical Composition Comprising Ivabradine Hydrochloride Polymorph Iv
Oppositions:
5
Patent:
EP3008064
Grant Date:
Nov 22, 2017
Title:
Stable Pemetrexed Arginine Salt And Compositions Comprising It
Oppositions:
1

Competitors of Synthon B.v.

LARSEN & BIRKEHOLM A/S

NOVARTIS AG

YEDA RESEARCH & DEVELOPMENT COMPANY, LTD.

Want to track Synthon B.v.?

Feel free to send us a message here and we will get back to you